Literature DB >> 27866715

Normohormonal primary hyperparathyroidism is a distinct form of primary hyperparathyroidism.

Megan K Applewhite1, Michael G White2, Jennifer Tseng2, Maryam K Mohammed2, Frederic Mercier2, Edwin L Kaplan2, Peter Angelos2, Tamara Vokes3, Raymon H Grogan2.   

Abstract

BACKGROUND: Normohormonal primary hyperparathyroidism presents diagnostic and intraoperative challenges, and current literature is conflicting about management. We aim to better define normohormonal primary hyperparathyroidism in order to improve the care for these patients.
METHODS: In the study, 516 consecutive patients undergoing parathyroidectomy for primary hyperparathyroidism were divided into 2 groups: classic primary hyperparathyroidism (classic primary hyperparathyroidism, increased serum levels of calcium, and parathyroid hormone) and normohormonal primary hyperparathyroidism (hypercalcemia, normal serum levels of parathyroid hormone). We evaluated inter-group differences in presentation, gland weight, pathology, and complications.
RESULTS: The normohormonal primary hyperparathyroidism group was comprised of 116 (22.5%) patients. Mean serum levels of parathyroid hormone and calcium were 62.1 pg/mL ± 10.1 and 10.6 mg/dL ± 0.63 in normohormonal primary hyperparathyroidism, and 142 ± 89.0pg/mL and 11.0 ± 0.88 (both P < .01) for classic primary hyperparathyroidism. Nephrolithiasis was more common in normohormonal primary hyperparathyroidism. Multigland hyperplasia was more common in normohormonal primary hyperparathyroidism 23 (19.8%) vs 44 (11%; P = .04). Concordant imaging studies were less likely in normohormonal primary hyperparathyroidism (82 [73.2%] vs 337 [87.1%; P < .01]), had a lesser total gland weight (531.8 mg ± 680.0 vs 1,039.6 mg ± 1,237.3; P < .01), and lesser 2-week parathyroid hormone (32.5 pg/mL ± 18.95 vs 41.0 pg/mL ± 27.8; P = .01). There was no difference in hypoparathyroidism (parathyroid hormone <15 pg/mL; P = .93) at 2 weeks postoperatively.
CONCLUSION: Normohormonal primary hyperparathyroidism represents 22.5% of our primary hyperparathyroidism population, which is greater than reported previously. It is a distinct disease process from classic primary hyperparathyroidism in presentation, imaging, and operative findings. More hyperplasia and a lesser gland weight make it challenging to resect the ideal amount of tissue. Studies with long-term follow-up are needed to determine optimal operative management.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27866715     DOI: 10.1016/j.surg.2016.03.038

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  8 in total

1.  Surgery for Primary Hyperparathyroidism with Normal Non-suppressed Parathyroid Hormone can be Both Challenging and Successful.

Authors:  Lauren E Orr; Travis J McKenzie; Geoffrey B Thompson; David R Farley; Robert A Wermers; Melanie L Lyden
Journal:  World J Surg       Date:  2018-02       Impact factor: 3.352

2.  Biochemical Profile Affects IOPTH Kinetics and Cure Rate in Primary Hyperparathyroidism.

Authors:  Claire E Graves; Catherine M McManus; John A Chabot; James A Lee; Jennifer H Kuo
Journal:  World J Surg       Date:  2020-02       Impact factor: 3.352

3.  Classic Primary Hyperparathyroidism Versus Normocalcemic and Normohormonal Variants: Do They Really Differ?

Authors:  Andreas Kiriakopoulos; Athanasios Petralias; Dimitrios Linos
Journal:  World J Surg       Date:  2018-04       Impact factor: 3.352

4.  Actual role of color-doppler high-resolution neck ultrasonography in primary hyperparathyroidism: a clinical review and an observational study with a comparison of 99mTc-sestamibi parathyroid scintigraphy.

Authors:  Giovanni Mariano Vitetta; Alberto Ravera; Giovanni Mensa; Luca Fuso; Pierluigi Neri; Alessandro Carriero; Stefano Cirillo
Journal:  J Ultrasound       Date:  2018-10-24

5.  Surgical management of MILD hyperparathyroidism.

Authors:  Adèle Lecourt; Gwenaëlle Creff; Paul Coudert; Olivier De Crouy Chanel; Pascal Guggenbuhl; Franck Jegoux
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-07-30       Impact factor: 2.503

Review 6.  Recent advances in the understanding and management of primary hyperparathyroidism.

Authors:  Melanie Goldfarb; Frederick R Singer
Journal:  F1000Res       Date:  2020-02-25

7.  A Novel Missense CASR Gene Sequence Variation Resulting in Familial Hypocalciuric Hypercalcemia.

Authors:  Panagiotis Bletsis; Rosemarie Metzger; J Alex Nelson; Justin Gasparini; Mahmoud Alsayed; Mira Milas
Journal:  AACE Clin Case Rep       Date:  2022-05-17

Review 8.  Advances in the diagnosis and the management of primary hyperparathyroidism.

Authors:  Ana Kashfia Islam
Journal:  Ther Adv Chronic Dis       Date:  2021-06-11       Impact factor: 5.091

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.